Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspectives on the pharmaceutical industry.

U E Reinhardt1

  • 1Princeton University, USA.

Health Affairs (Project Hope)
|September 18, 2001
PubMed
Summary
This summary is machine-generated.

This study offers an economic viewpoint on the pharmaceutical industry, highlighting that current criticisms often misdirect policy efforts. It argues for strengthening the consumer (demand) side rather than solely focusing on the pharmaceutical supply side.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health care for the aging baby boom: lessons from abroad.

The journal of economic perspectives : a journal of the American Economic Association·2004
Same author

Can efficiency in health care be left to the market?

Journal of health politics, policy and law·2002
Same author

Professor Uwe E. Reinhardt. James Madison Professor of Political Economy at the Woodrow Wilson School of Public and International Affairs at Princeton University.

New Jersey medicine : the journal of the Medical Society of New Jersey·2001
Same author

The defined-contribution paradox.

Health Forum journal·2001
Same author

Economists on academic medicine: elephants in a porcelain shop?

Health affairs (Project Hope)·2001
Same author

The economics of for-profit and not-for-profit hospitals.

Health affairs (Project Hope)·2001
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Market Analysis

Background:

  • The pharmaceutical industry faces significant public and regulatory criticism regarding drug pricing and access.
  • Existing critiques often focus on the supply side, including drug manufacturers and R&D costs.
  • There is a perceived imbalance in market dynamics, with limited attention to consumer behavior and information.

Purpose of the Study:

  • To analyze the pharmaceutical market through an economic lens, shifting focus from supply-side critiques.
  • To propose a policy framework that emphasizes empowering the demand side of the pharmaceutical market.
  • To identify the limitations of current approaches to pharmaceutical industry regulation and policy.

Main Methods:

  • Economic analysis of pharmaceutical market structures.

Related Experiment Videos

  • Review of existing literature on pharmaceutical industry criticism and policy.
  • Conceptual framework development for demand-side strengthening.

    • Main Results:

    • Current criticisms of the pharmaceutical industry are often misdirected, focusing ineffectively on the supply side.
    • Inaccurate perceptions contribute to flawed policy recommendations targeting pharmaceutical companies.
    • A significant opportunity exists to improve market efficiency by enhancing the demand side.

    Conclusions:

    • Policy interventions should prioritize strengthening the demand side of the pharmaceutical market.
    • Informed consumers and payers can drive more efficient market outcomes.
    • A paradigm shift from supply-side regulation to demand-side empowerment is recommended for the pharmaceutical sector.